Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Navitoclax and Sorafenib in Advanced Solid Tumors
NCT02143401Phase 1Completed
- Sponsor
- National Cancer Institute
- Start
- Jan 2015
- Primary completion
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of navitoclax in solid tumor and hepatocellular carcinoma (HCC), sponsored by National Cancer Institute. Primary endpoints: Maximum Tolerated Dose at 28 days and Incidence of Adverse Events up to 3 months. Started Jan 2015; status: completed.
02
Drugs
navitoclax
03
Conditions
solid tumorhepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT02143401.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02143401.